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Purpose: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and
shows activity in primary breast cancer (BC).
Methods: Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In
these patients we examined the pharmacokinetics of sorafenib and cyclophosphamide, toxicity of the regimen, the clinical response to
therapy and changes in the levels of biologically relevant biomarkers.
Results: Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with LþC. The mean
plasma concentrations of C were consistently lower following administration of LCS, compared with administration of LþC only. The
most common drug-related grade 3/4 adverse events were skin rash (69.3%), hand-foot skin reaction (69.3%) and diarrhoea (46.1%).
According to RECIST Criteria, a clinical complete response was observed in 6 of 13 patients. A significant reduction in tumour size,
evaluated with MRI, was also observed between baseline and 14 days of treatment in all 13 patients (P¼ 0.005). A significant reduction in
SUV uptake, measured by 18FDG-PET/CT, was observed in all patients between baseline and 30 days of treatment (P¼ 0.015) and
between baseline and definitive surgery (P¼ 0.0002). Using modified CT Criteria, a response was demonstrated in 8 out of 10 evaluable
patients at 30 days and in 11 out of 13 evaluable patients at the definitive surgery. A significant reduction in Ki67 expression was observed
in all patients at day 14 compared with baseline (Po0.00001) and in 9 out of 13 patients at the definitive surgery compared with baseline
(Po0.03). There was also a significant suppression of CD31 and VEGF-A expression in response to treatment (P¼ 0.01 and P¼ 0.007,
respectively).
Conclusions: The LCS combination is feasible and tolerable. The tumour response and target biomarker modulation indicate that the
combination is clinically and biologically active.
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Treatment with aromatase inhibitors (AIs), such as letrozole, has
demonstrated increased response rate compared with tamoxifen in
patients with breast cancer (BC) (Smith and Dowsett, 2003).
However, the development of resistance to endocrine therapy is a
significant problem involving the activation of other signalling
pathways such as EGFR, HER2, IGFR, MAPK, PI3K-AKT or PKC
(Nicholson et al, 2004, 2005; Osborne et al, 2005; Generali et al,
2009). This provides a strong rationale for combining endocrine
therapies with signal-transduction inhibitors to bypass endocrine
therapy resistance and achieve a more potent anti-tumour effect
(Gligorov et al, 2007; Johnston et al, 2007).
Sorafenib (Nexavar, BAY43-9006) is an oral multi-targeted
kinase inhibitor, which is capable of inhibiting several kinases
involved in tumour progression and angiogenesis (Iyer et al, 2010).
It was also recently shown that sorafenib can inhibit both mTOR
and (Kumar et al, 2007; Huynh et al, 2009) and MAPK signalling
(Keswani et al, 2008). Moreover, our preclinical data demonstrate
that the combination of letrozole with sorafenib in aromatase-
expressing BC cells shows a synergistic inhibition of cell
proliferation in vitro (Bonelli et al, 2010). We showed that
sorafenib inhibited BC-cell proliferation in a concentration-
dependent manner through a mechanism involving downregula-
tion of mTORC and its downstream targets p70S6K and 4E-
binding protein 1 (4E-BP1) (Bonelli et al, 2010). In BC cells treated
with letrozole and sorafenib, suppression of cell proliferation was
associated with enhanced accumulation of cells in the G0/G1 phase
of the cell cycle due to a downregulation of c-myc, cyclin D1 and
phospho-Rb expression (Bonelli et al, 2010). Moreover, experi-
ments involving long-term exposure to sorafenib showed that it
prevented the acquisition of resistance towards letrozole in BC cells
in vitro (Bonelli et al, 2010). These preclinical data provide a strong
rational for testing letrozole combined with sorafenib in patients
with BC.
Metronomic chemotherapy is the frequent administration of
cytotoxic drugs at a low dose that is designed to avoid dose-
limiting adverse effects that would require rest periods. In addition,
metronomic chemotherapy is proposed to target tumour growth
indirectly by inhibiting angiogenesis, rather than directly targeting
tumour cells (Pasquier et al, 2010). Our group has previously
shown that the combination of letrozole with a metronomic
regimen of cyclophosphamide is active in elderly patients with
primary BC (Bottini et al, 2006). These data do contrast with
studies that combined endocrine therapy with conventional high-
dose chemotherapy regimens, where the combination was shown
to be antagonistic (Osborne et al, 1989; Albain et al, 2009).
However, the favourable results we reported with metronomic
cyclophosphamide probably stem from the lower-toxicity profile
observed with this regimen and the fact that this therapy targets the
vascular compartment instead of targeting tumour cells directly.
On the basis of these findings, we have planned a randomised
phase II trial to explore the activity of the letrozole, metronomic
chemotherapy and sorafenib combination. This is a neoadjuvant
trial in postmenopausal breast cancer patients with ER positive,
HER2 negative primary breast cancer and is currently ongoing
(Eudract Number 2007-006208-39). In this paper, we present
pharmacokinetic, toxicity, response and biomarker data for this
regimen in the first thirteen consecutive patients enrolled in the
study before randomisation.
MATERIALS AND METHODS
Patients and treatment. This study involved 13 postmenopausal
women with ER positive, HER2 negative, T2-4, N0-1 BC enrolled
in a single institution. Inflammatory breast cancer was excluded
from the study. Eligibility criteria for inclusion were the same as
those described for our previous study, which examined the
combination of letrozole with metronomic cyclophosphamide in
BC (Bottini et al, 2006). Patients received one tablet (2.5mg) of
letrozole per day (Femara; Novartis), one tablet (50mg) of
cyclophosphamide per day (Endoxan; Baxter) and every 5th day
they received two tablets (400mg bid) of sorafenib (Nexavar,
Bayer). These drugs were given continuously for 6 months. At the
end of treatment the patients underwent definitive surgery. All
adverse events (AE) were graded by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC), version 3.0.
With regard to the pharmacokinetic profile, during the first 5
days the patients received only letrozole and cyclophosphamide.
The administration of sorafenib started from day 6 onwards. The
pharmacokinetic profile of sorafenib was assessed on day 29. The
pharmacokinetic profile of cyclophosphamide and 4-hydroxy-
cyclophosphamide was assessed on days 5 and 29. This approach
permitted us to test the safety and tolerability of this regimen and
the pharmacokinetic interaction between sorafenib and cyclopho-
sphamide. The decision to continue the study or not depended on
evaluations of tolerability, safety and pharmacokinetic profile of
cyclophosphamide after 6 weeks. A dose escalation was not
planned. If o33% of these patients experienced no significant
toxicity on the treatment, the study continued until the conclusion
of the pre-planned enrolment. If 33% or more of the patients
experienced a significant toxicity during the treatment, the study
would have been closed due to unacceptable toxicity. The dose-
limiting unacceptable toxicity was defined by the following adverse
events during the first cycle that could be correlated to the drug
combination:
1. Haematological toxicity:
Neutropenia o0.5 109 l 1 not associated with fever lasting
longer than 10 days
Neutropenia o0.5 109 l 1 associated to fever 438.5 1C
Piastrinopenia o25 109 l 1 or grade 3 piastrinopenia associated
with bleeding
2. Non-haematological toxicity:
grade 3–4 non-haematological toxicity with the exclusion of:
a. allergic reactions controlled by an adequate therapy
b. grade 4 hypertension crises related to sorafenib
c. grade 3 hypertension
Any toxicity correlated to the study drug was unacceptable
according to the opinion of the investigators.
Pharmacokinetic analysis. The pharmacokinetic analysis was
performed in the Laboratory of Dr Frank-Thorsten Hafner (Bayer
HealthCare AG, Preclinical Pharmacokinetics—Bioanalytics,
Pharma Research Center, Building 468 D-42096 Wuppertal,
Germany). For measurement of sorafenib, plasma samples were
collected on day 1 of Cycle 2 (Day 29) following multiple dosing of
both 400mg bid sorafenib and 50mg of cyclophosphamide in
combination with 2.5mg of letrozole (see Figure 1A). Plasma
samples from 13 patients were collected before dosing and at 0.5, 1,
2, 4, 8, 10 and 12 h after dosing. For measurement of cyclopho-
sphamide and its metabolite 4-hydroxy-cyclophosphamide, plasma
samples were collected on Day 5 of Cycle 1 (before sorafenib
treatment) and on Day 1 of Cycle 2 (Day 29) (after concomitant
treatment with multiple oral doses of both drugs) (see Figure 1A).
This allowed us to evaluate the effect of multiple oral doses of
sorafenib on the pharmacokinetics of cyclophosphamide. Plasma
samples from 13 patients were collected before dosing and at 0.25,
0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after dosing. The
concentration of the drugs was assessed by using a one-way
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analysis of variance model for dose-normalised and log-trans-
formed maximum observed serum concentration considering the
concentration-time curve (AUC). Statistical significance of the
factor of dose was set at P¼ 0.05.
Response assessment. The size of the primary tumour and the
axillary lymph nodes was measured monthly with callipers by the
same clinician. Tumour size measurements obtained by breast
MRI, using protocols described elsewhere (Bonelli et al, 2010),
were made at baseline and at the 14th day of treatment and were
independently reviewed by two experienced radiologists. Any
discrepant readings were resolved by consensus. Response
evaluated by either clinical palpation or breast MRI was assessed
by the measurement of the changes in the product of the two
largest diameters recorded at baseline, at the 14th day and at the
end of therapy before surgery, according to the RECIST Criteria.
The 18FDG-PET/CT scans (CT 8 slice) were carried out using
a Discovery ST PET/CT scanner (GE Healthcare, Milwaukee,
WI, USA) and performed at baseline, after 30 days of treatment
and before definitive surgery. The 18FDG-PET/CT images were
read independently by two experienced radiologists. Standardised
uptake values (SUVs) were calculated. Lesions were scored for
response by Modified CT Criteria using 18FDG-PET/CT scans
obtained at baseline, after 30 days of treatment and just before
definitive surgery. Lesions were scored as follows: CR (disappear-
ance of lesion), PR (decrease in tumour size of X10% or decrease
in tumour density of X15%), SD (does not meet the criteria for
CR, PR or PD) and PD (an increase in tumour size of X10% and
does not meet criteria of PR by tumour density on CT) (Choi et al,
2007).
The observers were blinded for any clinical data including the
site of the primary tumour. Discrepancies were resolved by
consensus. During the study, clinicians and pathologists were
blinded to the 18FDG-PET/CT related data.
Collection and processing of tissue samples. Tissue was obtained
from patients at three time points: tissue from incision biopsy
performed at presentation, tissue from tru-cut biopsy performed
after 14 days of treatment and tissue obtained at definitive surgery.
Surgery (quadrantectomy or mastectomy) was planned after full
clinical reassessment. All patients subjected to quadrantectomy
underwent irradiation of the residual breast (60 Gys delivered in 6
weeks). Immunohistochemistry was performed on paraffin-
embedded tumour samples obtained at all three time points.
HER-2, ER, PgR, Ki67, CD31 and VEGF-A staining was performed
using standard protocols as described elsewhere (Koukourakis et al,
2005; Bottini et al, 2006).
Statistical analysis. Ki67, CD31, VEGF-A, MRI and SUVmax were
analysed as continuous variables. Non-parametric statistical
methods (Mann–Whitney test for unpaired data, Wilcoxon’s
matched-pairs signed-rank test for paired data, Spearman Rho
for simple correlation analysis) were used in the primary analyses
of the data. The PK analysis was carried out using ANOVA test. All
tests were two-sided; Po0.05 was considered as statistically
significant. Statistical analysis was performed on an IBM-
compatible personal computer using Statistica software (Statsoft,
Tulsa, OK, USA) for Windows (Microsoft, Redmond, WA, USA)
software.
Ethical approval. The Local Ethical Committee of A.O. Istituti
Ospitalieri di Cremona approved this prospective study and signed
informed consent was obtained from each patient.
RESULTS
Details of the study population. Thirteen postmenopausal
women (median 67 years old, range 53–79) with T2-4, N0-1 (11
patients with T2, and 2 with T4, 6 with node negative and 7 with
node positive, 5 with grade 2 and 8 with grade 3) and ERþ ve
(13/13) and HER2-ve (0/13) BC were prospectively enrolled
between April 2009 and May 2010 into the trial. See Table 1A and
1B for details of patient characteristics.
Pharmacokinetic analysis of sorafenib. We examined whether
the pharmacokinetics of sorafenib were affected when sorafenib
was dosed in combination with letrozole and metronomic
cyclophosphamide. Plasma samples were collected on day 1 of
Cycle 2 (Day 29) at which time point patients had already received
multiple doses of sorafenib, cyclophosphamide and letrozole
(Figure 1A). Plasma samples from 13 patients were collected
before dosing and at 0.5, 1, 2, 4, 8, 10 and 12 h after dosing. A time
course of circulating sorafenib concentrations is shown in
Figure 2A. The results for AUC (0–12) and Cmax of sorafenib for
Day 1 of Cycle 2 are given as individual and geometric mean values
(see Table 1A). The geometric means for AUC (0–12) and Cmax
calculated were within the range of values observed after multiple
dosing with 400mg per b.i.d. sorafenib in previous studies
(Strumberg et al, 2005, 2007). These findings show that circulating
concentrations of sorafenib were not significantly affected by
dosing in combination with cyclophosphamide and letrozole.
Pharmacokinetic analysis of cyclophosphamide. We then exam-
ined whether dosing of sorafenib affects the pharmacokinetics of
cyclophosphamide. Plasma samples were collected on Day 5 of
Cycle 1 (before sorafenib treatment) and on Day 1 of Cycle 2 (Day
29) (after concomitant treatment with multiple oral doses of both
sorafenib and cyclophosphamide) (see Figure 1A). This allowed us
to evaluate the effect of multiple oral doses of sorafenib on the
pharmacokinetics of cyclophosphamide. Although cyclophospha-
mide was measurable in all samples up to 12 h, only a few isolated
plasma samples obtained at 24 h contained concentrations above
the lower limit of quantification (LLOQ), so we limited our
pharmacokinetic analysis to the time points up to 12 h. Geometric
mean plasma concentration time courses of cyclophosphamide
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Figure 1. (A) Schematics illustrating the design of the study.
(B) Pharmacodynamic profile of the study.
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obtained in patients before and after exposure to sorafenib are
shown in Figure 2A. The results for AUC (0–24), Cmax and t1/2 of
cyclophosphamide for Day 5 of Cycle 1 and for Day 1 of Cycle 2
are given as individual and geometric mean values in Table 1B.
Mean plasma concentrations of cyclophosphamide were consis-
tently lower following concomitant administrations of sorafenib
and letrozole compared with concomitant administration of
letrozole alone (Figure 2B). This trend was confirmed by the
comparison of corresponding AUC (0–24) and Cmax values from
Day 5, Cycle 1 and Day 1 of Cycle 2. AUC (0–24) of
cyclophosphamide was consistently lower in all subjects when
both drugs were co-administered, on average by 29% (Table 1B).
Cmax was also reduced in most subjects on Day 1 of Cycle 2 but to a
lesser degree, on average by 12%. The decrease in AUC (0–24) was
accompanied by a corresponding decrease in t1/2, on average by
27%. These data indicate that concomitant administration of
sorafenib moderately decreases the exposure to cyclophosphamide.
Toxicity assessment. We did not observe particular haematolo-
gical toxicity; only neutropenia grade 1–2 (38.5% of the cases) and
grade 3 (7.7% of the cases). The non-haematological toxicity of
letrozole and cyclophospamide in combination with sorafenib was
mainly grade 1 or 2 as reported in Table 2. The most common
drug-related grade 3–4 adverse events were skin rash (69.3%),
hand-foot skin reaction (69.3%), diarrhoea (46.1%). Examples of
skin rash and hand-foot skin reaction are depicted in Figure 3A
and B, respectively. Dosing interruptions or reductions due to an
AE did not occur.
Response assessment by palpation, mammography and patho-
logy. Complete response by clinical palpation, evaluated at the end
of treatment before definitive surgery, was observed in 6 out of 13
patients (46%), whereas partial response was observed in the
remaining 7 patients (54%). Complete response by mammography
was observed in 5 out of 13 patients (38.4%), whereas partial
response was observed in the remaining 8 patients (61.6%) before
definitive surgery. At the definitive surgery, we observed two
patients with pT1b tumour, three patients with pT1c tumour, five
patients with pT2 tumour, two patients with pT4b tumour, with 11
out of 13 patients having lymph node involvement. No change of
tumour grading between the baseline sample and post-treatment
samples was noted. None of the enrolled patients showed a post-
treatment pathologic complete response.
Imaging assessment by MRI, FDG-PET and Modified CT
criteria. Tumour response was assessed by an MRI scan at
baseline and at 14 days of treatment (Figure 1B). Median tumour
size evaluated by an MRI was 31mm (range 17–90mm) at
baseline, 27mm (range 11–90mm) at day 14 with a small but
statistically significant reduction in tumour size being observed in
all 13 patients at day 14 (P¼ 0.005).
Table 1A. Preliminary pharmacokinetic parameters of
sorafenib following multiple doses of 400mg per b.i.d.
sorafenib in combination with 50mg of cyclophosphamide
and 2.5mg of letrozole on Day 1 of Cycle 2
Patient No.
AUC(0–12)
(mgh l1) Cmax (mg l
 1)
1 80.2 8.40
2 101 10.7
3 263 23.2
5 45.7 4.98
6 56.0 5.73
7 86.8 11.4
8 103 11.6
9 46.3 6.10
10 79.0 9.00
11 113 16.4
12 41.7 4.22
13 94.5 17.6
Geometric mean 82.7 9.77
Geometric s.d. 1.64 1.68
Table 1B. Preliminary pharmacokinetic parameters of cyclophosphamide following multiple doses of 50mg od
cyclophosphamide in combination of 2.5mg of letrozole without (Day 5, Cycle 1) and after concomitant treatment (Day 1,
Cycle 2) with multiple oral doses of 400mg bid sorafenib
AUC(0–24) (mgh l 1) Cmax (mg l
 1) t1/2 (h)
Patient No. Cycle 1 Cycle 2
Ratio cycles
2/1 Cycle 1 Cycle 2
Ratio cycles
2/1 Cycle 1 Cycle 2
1 22.4 21.4 0.96 1.86 1.89 1.02 13.7 9.86
2 20.1 12.1 0.60 2.28 1.61 0.71 7.56 4.74
3 19.7 10.7 0.54 1.91 1.13 0.59 8.13 7.41
5 6.58 5.51 0.84 1.57 1.43 0.91 3.25 3.10
6 19.8 14.4 0.73 2.60 2.29 0.88 8.46 6.83
7 12.0 7.99 0.67 1.56 1.44 0.92 6.16 4.52
8 16.6 12.9 0.78 2.19 2.67 1.22 7.25 5.04
9 21.1 17.8 0.84 2.20 2.12 0.96 8.76 7.15
10 19.3 17.1 0.89 1.98 1.80 0.91 9.27 7.29
11 35.2 21.2 0.60 2.74 1.99 0.73 13.8 8.88
12 14.9 10.2 0.68 1.72 1.48 0.86 5.81 3.69
13 11.7 8.17 0.70 2.07 1.90 0.92 5.84 3.92
Meana 16.7 11.9 0.71 2.01 1.77 0.88 7.39 5.43
S.d.b 1.50 1.52 1.20 1.19 1.26 1.20 1.48 1.47
aGeometric means.
bGeometric s.d.
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The metabolic activity of the tumours was evaluated by a 18FDG
-PET/CT scan at baseline (PET1), after 1 month of treatment
(PET2) and at the end of the treatment before definitive surgery
(PET3) for all 13 patients (Figures 1B, 4A and 4B). At PET1 the
mean average SUVmax was 5.01 with a median of 4.5 (range 1.8–
12). At PET 2 the mean average SUVmax was 2.39 with a median of
1.9 (range 0–4.5). At PET3 the mean average SUVmax was 0.71
with a median of 0 (range 0–3.9). In this series of patients we
identified a significant reduction between PET1 and PET2
(P¼ 0.015), between PET2 and PET3 (P¼ 0.006) and between
PET1 and PET3 (P¼ 0.0002) (Figure 4B).
We also monitored the SUVmax in the lymph nodes. At baseline,
10 out of 13 patients presented a positive uptake suggesting tumour
involvement of lymph nodes. After 1 month of treatment, seven
patients showed a reduction in SUVmax values in the lymph nodes.
By the end of treatment, all of the patients had a complete
metabolic response in the lymph nodes and in the remaining
patients the lymph nodes still showed lower metabolic activity
compared with baseline. The average of the SUVmax at PET1 was
2.89 (median¼ 2.50, range 1.1–7.1); at PET2 it was 1.52
(median¼ 1.30, range 0–3.3) and at PET3 it was 0.17 (median¼ 0,
range 0–1.7). A significant reduction of SUVmax in the lymph nodes
was therefore observed between PET1 and PET2 (P¼ 0.045), PET2
and PET3 (P¼ 0.0008), and PET1 and PET3 (P¼ 0.0002). Using the
Modified CT Criteria (Choi et al, 2007), to evaluate response at 30
days and response just before surgery, our study showed response
(CR or PR) in 8 patients and 2 patients with stable disease (n¼ 10
evaluable patients) at 30 days and a response in 11 patients (n¼ 11
evaluable patients) at definitive surgery (Table 3).
Assessment of biological markers. Biological markers were
assessed in samples obtained at baseline, at 14 days and at
definitive surgery (Figure 1B). Ki67 labelling index was assessable
in 11 of the 13 patients, but there was insufficient tissue available
for the remaining two patients. At baseline the mean average Ki67
index was 20.69% with median of 20% (range 8–36), at day 14 the
mean was 10.64% with median of 10% (range 1–20) and at
Table 2. Adverse Events
Adverse Events Grade 1 or 2 Grade 3 or 4
Hand-foot syndrome 4 (30.7%) 9 (69,3%)
Fatigue 4 (30.7%) 1 (7.7%)
Rash 4 (30.7%) 9 (69.3%)
Emesis 0 0
Hypertension 2 (15.4%) 0
Nausea 0 0
Arthralgias 3 (23%) 0
Diarrhea 2 (15.4%) 6 (46.1%)
Dehydration 4 (30.7%) 2 (23%)
Infection 0 0
Anorexia 4 (30.7%) 0
Headache 1 (7.7%) 0
Mucositis 2 (15.4%) 0
Elevated liver function tests 0 0
Rigors/chills 1 (7.7%) 0
Joint function 3 (23%) 1 (7.7%)
Neutropenia 5 (38.5%) 1 (7.7%)
Dyspnea 0 0
Acne 3 (23%) 1 (7.7%)
Hypotension 0 0
Hypophosphatemia 0 0
Alopecia 10 (76.9%) 0
Sensory neuropathy 5 (38.5%) 0
Weight loss 5 (38.5%) 0
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Figure 2. Pharmaockinetics of sorafenib and cyclophosphamide. (A)
Plasma concentrations of sorafenib following multiple doses of 400mg
per b.i.d. sorafenib in combination with 50mg of cyclophosphamide
and 2.5mg of letrozole on Day 1 of Cycle 2 (geometric means,
geometric s.d.; n¼ 13). (B) Plasma concentrations of cyclophosphamide
(*) following multiple doses of 50mg of cyclophosphamide in
combination with 2.5mg of letrozole without (Day 5, Cycle 1) and after
concomitant treatment (Day 1, Cycle 2) with multiple oral doses of
400mg per b.i.d. sorafenib (G.M.¼geometric means, G.s.d.¼
geometric standard deviation; n¼ 13) *More than one-third of
individual plasma concentrations were below LLOQ at 24h after dosing
on both profile days. No corresponding geometric mean
concentrations was calculated.
Figure 3. Common drug-related adverse events. (A) Grade 2 skin rash.
(B) Grade 2 hand-foot syndrome. Both of these reactions are adverse
events related to the treatment with sorafenib.
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definitive surgery the mean was 11.38% with median of 7% (range
0–34) (Figure 5A). We observed a marked suppression of the Ki67
proliferation index after 14 days in the 11 patients that could be
evaluated (Po0.00001), and there was a significant reduction in
Ki67 index at definitive surgery compared with baseline (P¼ 0.03).
However, 4 patients out of the 11 evaluated showed an increase in
Ki67 index at definitive surgery. At the end of treatment, these four
patients showed a clinical partial response, which corresponded to
a pT2 and pT4 at the pathology report. It is possible that these four
patients experienced early-onset resistance to the therapeutic regimen.
Change in expression of the angiogenesis-related markers CD31
and VEGF-A was also evaluated (Figure 5B). CD31 expression could
be evaluated in 10 of the 13 patients at baseline (median
expression¼ 3, range 1–5), in 8 out of 13 at day 14 (median
expression¼ 1, range 1–3) and in 8 out of 13 at definitive surgery
(median expression¼ 1, range 1–3). The CD31 expression showed a
significant reduction at day 14 (P¼ 0.006) and at definitive surgery
(P¼ 0.01) compared with baseline. VEGF-A expression could be
evaluated in 9 of the 13 patients at baseline (median expression¼ 2,
range 1–2), in 8 out of 13 at day 14 (median expression¼ 1, range
1–3) and in 9 out of 13 at definitive surgery (median expression¼ 1,
range 1–3). No significant difference in VEGF-A expression was
found between baseline and day 14, but a significant reduction at the
definitive surgery compared with baseline was observed (P¼ 0.007)
(Figure 5B). A correlation was observed between the decrease in
CD31 and the decrease in VEGF-A expression, both at day 14
(Po0.0001) and at the definitive surgery (Po0.0001).
DISCUSSION
Endocrine resistance presents a major challenge in the manage-
ment of ERþ ve breast cancer and is an area under intense
investigation. Non-genomic cross-talk between ER and growth
factor receptors can activate intracellular signalling cascades
involved in oestrogen-independent growth, such as the Ras-Raf-
mitogen-activated protein kinase (MAPK) (Massarweh et al, 2008)
and the phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR path-
ways (Johnston et al, 2005). Moreover, both MAPK and AKT can
directly enhance the classic genomic transcriptional activity of ER
in the absence of oestrogens (Le Goff et al, 1994) further
contributing to endocrine resistance. It has been shown that
letrozole-based treatment is able to significantly reduce PI3K and
phospho-mTOR expression (Generali et al, 2008) and that HIF-
1alpha and p44/42 MAPK expression is independent factor for
endocrine resistance in neoadjuvant setting (Generali et al, 2009).
These data suggest that targeting these pathways could potentiate
the aromatase inhibitor effect, preventing or postponing the onset
of endocrine resistance. Therefore, combined inhibition of the
oestroge pathway and growth factor signalling represents an
attractive target for pharmacological intervention. Sorafenib is an
oral multikinase inhibitor, capable of inhibiting mTOR signalling
and HIF-1alpha expression (Kumar et al, 2007; Huynh et al, 2009)
or MAPK expression and related proliferation proteins (Keswani
et al, 2008). Our previous in vitro experiments with the
combination of letrozole and sorafenib demonstrated a potential
role for this combination in the treatment of hormone-dependent
BC cells (Bonelli et al, 2010). However, to date, the combination of
sorafenib with letrozole and metronomic administration of
cyclophosphamide has never been tested in a clinical setting. We
have therefore investigated the pharmacology, toxicity and efficacy
of this regimen in primary breast cancer patients.
Pharmacokinetic analysis showed there was no impact of the
combination regimen on the circulating levels of sorafenib in
patients. Moreover, the analysis of the pharmacokinetic data
showed that there was no relevant impact of sorafenib (400mg
BID) on the pharmacokinetics of cyclophosphamide when these
compounds were co-administered. However, the data do indicate
that concomitant sorafenib moderately decreased the exposure
(Cmax and AUC0–24) to cyclophosphamide, without being influ-
enced by the sorafenib total dose. Indeed it is recognised that
cyclophosphamide is a potent inducer of microsomal enzymes and
is able to increase levels of CYP2C8, 2C9 and 3A4 inducing its own
metabolism (Chang et al, 1997). As previously shown, a similar
induction by cyclophosphamide of human CYP2B6 and 3A4
enzyme expression occurs (Gervot et al, 1999; Lindley et al, 2002).
This auto-induction in cyclophosphamide metabolism is detectable
within 24 h after the start of the treatment and might explain the
reduction of cyclophosphamide plasma concentrations. However,
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Figure 4. Measurment of responses with 18FDG PET/CT imaging. (A) Example images of 18FDG PET/CT scan obtained from the same
patient before (PET1) and after treatment (PET3). A change in the metabolic activity of the tumour between baseline and end of the treatment is
clearly observed. (B) Tumour SUVmax values by the
18FDG PET/CT scan. The trend of the tumour metabolic activity during treatment for each
patient. A significant reduction in SUVmax has been quantified in all thirteen patients from baseline to the definitive surgery (P-value: between PET1
and PET2 (P¼0.015), between PET2 and PET3, (P¼ 0.006) and between PET1 and PET3 (P¼ 0.0002)).
Table 3. Response scored using Modified CT Criteria
Number of patients (%)
CR PR SD PD
30 days time pointa 1 7 2 0
Definitive surgery time pointb 7 4 0 0
Abbreviations: CR¼ complete response; PD¼progressive disease; PR¼partial response;
SD¼ stable disease.
a(n¼ 13 patients; in 3 out of 13 patients data were not available).
b(n¼ 13 patients; in 2 out of 13 patients data were not available).
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further investigation in a larger population of cancer patients and a
more accurate evaluation of all cyclophosphamide-derived meta-
bolites is warranted.
The metronomic administration of chemotherapy compounds is
a good treatment option for breast cancer patients, has a low-
toxicity profile and high efficacy in most patients (Montagna et al,
2014). We previously demonstrated that co-administration of
endocrine therapy with the metronomic administration of
cyclophosphamide is well tolerated without any particular adverse
events (Bottini et al, 2006).
In the current study, we show that sorafenib administered with
cyclophosphamide and letrozole had a safety profile consistent
with that of the individual agents in patients with breast cancer.
The most common toxicities were skin rash, hand-foot skin
reaction and diarrhea Although all are reported to be associated
with sorafenib (Gomez & Lacouture, 2011), it is difficult to
determine whether sorafenib was the sole agent responsible for the
relative high incidence of these events among the enrolled patients.
Across three phase 2 randomised studies where advanced breast
cancer patients were treated with sorafenib in combination with
chemotherapy (Baselga et al, 2012; Gradishar et al, 2013;
Schwartzberg et al, 2013), the incidence of hand-foot syndrome,
rash and diarrhea was 31–44, 2–4 and 3–6%, respectively. By
comparison, the incidence of hand-foot syndrome (69.3%), rash
(69.3%) and diarrhea (46.1%) was elevated in our study. On the
contrary, the incidence of other grade 3/4 toxicities reported in our
study, such as fatigue and neutropenia, was similar to those
reported in these previous studies that combined chemotherapy
with sorafenib. However, despite this incidence of toxicity, in our
experience the timely detection of adverse events in patients helps
to mitigate their clinical consequences.
It is also of interest to compare the toxicity profile of LCS with a
previous study that combined endocrine therapy with sorafenib in
breast cancer. Isaacs et al (2011) reported a phase I/II study that
employed a combination of sorafenib and anastrazole in patients
with metastatic breast cancer. In that study, 77% of patients
required dose reductions of sorafenib and 31% came off study due
to toxicity. The most common grade 3/4 toxicities were hand-foot
syndrome (34%), fatigue (17%), rash (11%), emesis (11%) and
hypertension (11%). Among the 35 women enrolled into that
phase I/II trial, 46% had an ECOG X1, 23% had visceral
metastasis, 43% had bone metastasis and all had received one or
two lines of previous therapy. In contrast, the women enrolled in
our study were naive of any treatment and without any visceral/
bone involvement. These differences in the patient populations
may explain the different toxicity profile reported by our group in
comparison with the study by Isaacs et al (2011).
Clinical anti-cancer activity (complete and partial responses)
was observed in all patients. This was objectively confirmed by the
18FDG-PET/CT scan, with decreased SUVmax values observed in
all 13 patients after treatment. However, FDG PET/CT failed to
detect 11 instances of isolated tumour cells, micro-embolic or
plural-embolic in axillary nodes, which were reported in the
definitive pathological report. In some studies the role of FDG
PET/CT in the axillary staging of breast cancer has been
questioned with FDG PET/CT proving to have poor sensitivity
compared with immunohistochemistry on lymph nodes biopsy in
which multistep sectioning is commonly used to identify axillary
micrometastases (that is, clusters of malignant cells 40.2mm to
p2.0mm in diameter) (Guller et al, 2002; Kelemen et al, 2002; van
der Hoeven et al, 2002). Thus, the limited spatial resolution of the
current FDG PET/CT scanners in comparison with the more
accurate pathological examination techniques is a reason for these
modest results of PET in the detection of micro-metastases.
The Ki67 labelling index after 2 weeks of therapy and at
definitive surgery was significantly lower than the labelling index at
the baseline for eight patients. In particular, we noticed that the
reduction of Ki67 expression was greater between the beginning
and the end of the treatment than after 15 days of treatment. Taken
together, these data suggest that the tried and tested letrozole-
cyclophosphamide combination (Bottini et al, 2006) with sorafenib
is promising in terms of metabolic activity and suppression
proliferation index. Of note, however, are four patients that did not
show a reduction in tumour proliferation activity at the end of the
treatment. As previously described by Dowsett et al (2005), this
might be an indicator of endocrine resistance. However, Ki67 may
not be the most reliable indicator of tumour cell proliferation. As
Dowsett et al (2005) have proposed, to better investigate the anti-
proliferative effect of therapy, it might be more appropriate to
analyse other indices of cell proliferation, such as S phase markers
or MCM2.
Previous reports showed the metronomic schedule is able to
modulate several factors, such as VEGF-A, circulating endothelial
cells and fibroblast growth factor 2, which are all involved in
remodelling of cancer vessels (Mancuso et al, 2006; Calleri et al,
2009; Isaacs et al, 2011). Our group has shown that the
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Figure 5. Analysis of molecular markers. (A) Ki67 labelling index at baseline, day 14 and at the definitive surgery. Proliferation trend is reported for
each patient. A significant reduction in mean average proliferation index is observed between baseline and day 14 (P¼0.00001) and between
baseline and end of treatment (P¼0.031). (B) Immunohistochemistry demonstrating the expression of angiogenesis-related markers (CD31 and
VEGF-A) in pre-treatment and post-treatment samples.
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combination of letrozole and metronomic cyclophosphamide has
an anti-angiogenic effect with a significant reduction of VEGF-A
after 6 months of neoadjuvant treatment (Bottini et al, 2006). Here
we investigated the expression of two robust markers, CD31 and
VEGF-A, supported also by published data on their modulation
and their correlation with treatment response to bevacizumab
(Yang et al, 2008). The expression of CD31 and VEGF-A was
significantly decreased after treatment, supporting the contention
that the administered regimen has an anti-angiogenic effect in
primary BC.
In this study, we also used the breast MRI technique as a more
accurate method than breast ultrasound and mammography or
clinical palpation (Bodini et al, 2004) in evaluating the disease
response to therapy and because of its ability to delineate anatomic
detail of breast cancers. In our study, there was only a modest
evidence of significant changes in tumour dimensions after 14 days
of treatment, maybe due to the short interval between the two
evaluations. In the future, it would be preferable to perform the
breast MRI at time points further into treatment to monitor
properly any differences in clinical response induced by the
treatment (Bodini et al, 2004). Moreover, improvements in an MRI
technology for the monitoring of blood-flow as a marker of tumour
angiogenesis (Mehta et al, 2011) are warranted in future trials
containing anti-angiogenic drugs such as sorafenib and or
metronomic cyclophosphamide.
In conclusion, the addition of sorafenib to the already tested
letrozole-cyclophosphamide combination was associated with a
clinical response, a significant decrease in tumour metabolic
activity, in proliferation index and in angiogenesis in patients with
hormone receptor positive primary breast cancer. Conceivably, this
benefit may be due to the ability of sorafenib to overcome
resistance to endocrine therapy and/or the increased anti-
angiogenic activity when sorafenib is combined with the
metronomic administration of cyclophosphamide.
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